DDInter107 DDInter782
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements. It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors. In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or. Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Apalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eplerenone
Apalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Polatuzumab vedotin
Apalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anisindione
Apalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Delafloxacin
Apalutamide {u} may lead to a major life threatening interaction when taken with {v} Isavuconazonium
Apalutamide {u} may lead to a major life threatening interaction when taken with {v} Abemaciclib
Apalutamide may cause a minor interaction that can limit clinical effects when taken with Eplerenone
Apalutamide may cause a minor interaction that can limit clinical effects when taken with Polatuzumab vedotin
Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin
Apalutamide may lead to a major life threatening interaction when taken with Isavuconazonium
Apalutamide may lead to a major life threatening interaction when taken with Abemaciclib